Immune checkpoint blockade: Releasing the brake towards hematological malignancies

Blood Reviews

Volumn 30, Issue 3, 2016, Pages 189-200

  Xia, Yi ^a   Medeiros, L Jeffrey ^a   Young, Ken H ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Lymphoid malignancies; Nivolumab; PD 1; PD L1; PD L2; Pembrolizumab; Pidilizumab

Indexed keywords

CANCER VACCINE; CD28 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB; NIVOLUMAB; PEMBROLIZUMAB; PIDILIZUMAB; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ANTINEOPLASTIC AGENT; PDCD1LG2 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 2; TUMOR MARKER;

ABDOMINAL PAIN; ACUTE MYELOBLASTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTATION; B CELL LYMPHOMA; CANCER RADIOTHERAPY; CELL CYCLE CHECKPOINT; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL PRACTICE; DIARRHEA; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; FATIGUE; FOLLICULAR LYMPHOMA; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HUMAN; HYPERTHYROIDISM; IMMUNOREGULATION; LARGE CELL LYMPHOMA; MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; NONHUMAN; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HEMATOLOGIC DISEASE; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MULTIMODALITY CANCER THERAPY; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME;

ANIMALS; ANTINEOPLASTIC AGENTS, IMMUNOLOGICAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; B7-H1 ANTIGEN; BIOMARKERS, TUMOR; COMBINED MODALITY THERAPY; CTLA-4 ANTIGEN; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOMODULATION; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 LIGAND 2 PROTEIN; PROGRAMMED CELL DEATH 1 RECEPTOR; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84950254702     PISSN: 0268960X     EISSN: 15321681     Source Type: Journal    
DOI: 10.1016/j.blre.2015.11.003     Document Type: Review

References (108)

1. Topalian S.L., Drake C.G., Pardoll D.M. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 2015, 27:450-461.
2. Linsley P.S., Ledbetter J.A. The role of the CD28 receptor during T cell responses to antigen. Annu Rev Immunol 1993, 11:191-212.
3. Teft W.A., Kirchhof M.G., Madrenas J. A molecular perspective of CTLA-4 function. Annu Rev Immunol 2006, 24:65-97.
4. Naluai A.T., Nilsson S., Samuelsson L., Gudjonsdottir A.H., Ascher H., Ek J., et al. The CTLA4/CD28 gene region on chromosome 2q33 confers susceptibility to celiac disease in a way possibly distinct from that of type 1 diabetes and other chronic inflammatory disorders. Tissue Antigens 2000, 56:350-355.
5. Balzano C., Buonavista N., Rouvier E., Golstein P. CTLA-4 and CD28: similar proteins, neighbouring genes. Int J Cancer Suppl 1992, 7:28-32.
6. Waterhouse P., Penninger J.M., Timms E., Wakeham A., Shahinian A., Lee K.P., et al. Lymphoproliferative disorders with early lethality in mice deficient in ctla-4. Science 1995, 270:985-988.
7. Egen J.G., Allison J.P. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 2002, 16:23-35.
8. Collins A.V., Brodie D.W., Gilbert R.J., Iaboni A., Manso-Sancho R., Walse B., et al. The interaction properties of costimulatory molecules revisited. Immunity 2002, 17:201-210.
9. Freeman G.J., Long A.J., Iwai Y., Bourque K., Chernova T., Nishimura H., et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
10. Rudd C.E., Taylor A., Schneider H. CD28 and CTLA-4 coreceptor expression and signal transduction. Immunol Rev 2009, 229:12-26.
11. Schneider H., Downey J., Smith A., Zinselmeyer B.H., Rush C., Brewer J.M., et al. Reversal of the TCR stop signal by CTLA-4. Science 2006, 313:1972-1975.
12. Qureshi O.S., Zheng Y., Nakamura K., Attridge K., Manzotti C., Schmidt E.M., et al. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 2011, 332:600-603.
13. Munn D.H., Sharma M.D., Mellor A.L. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004, 172:4100-4110.
14. Wing K., Onishi Y., Prieto-Martin P., Yamaguchi T., Miyara M., Fehervari Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 2008, 322:271-275.
15. Jain N., Nguyen H., Chambers C., Kang J. Dual function of CTLA-4 in regulatory T cells and conventional T cells to prevent multiorgan autoimmunity. Proc Natl Acad Sci U S A 2010, 107:1524-1528.
16. Tang Q., Bluestone J.A. The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat Immunol 2008, 9:239-244.
17. Wing J.B., Ise W., Kurosaki T., Sakaguchi S. Regulatory T cells control antigen-specific expansion of Tfh cell number and humoral immune responses via the coreceptor CTLA-4. Immunity 2014, 41:1013-1025.
18. Sage P.T., Paterson A.M., Lovitch S.B., Sharpe A.H. The coinhibitory receptor CTLA-4 controls B cell responses by modulating T follicular helper, T follicular regulatory, and T regulatory cells. Immunity 2014, 41:1026-1039.
19. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., et al. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 2001, 291:319-322.
20. Intlekofer A.M., Thompson C.B. At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol 2013, 94:25-39.
21. Keir M.E., Butte M.J., Freeman G.J., Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008, 26:677-704.
22. Keir M.E., Latchman Y.E., Freeman G.J., Sharpe A.H. Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J Immunol 2005, 175:7372-7379.
23. Keir M.E., Liang S.C., Guleria I., Latchman Y.E., Qipo A., Albacker L.A., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med 2006, 203:883-895.
24. Oestreich K.J., Yoon H., Ahmed R., Boss J.M. NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 2008, 181:4832-4839.
25. Terawaki S., Chikuma S., Shibayama S., Hayashi T., Yoshida T., Okazaki T., et al. IFN-alpha directly promotes programmed cell death-1 transcription and limits the duration of T cell-mediated immunity. J Immunol 2011, 186:2772-2779.
26. Yokosuka T., Takamatsu M., Kobayashi-Imanishi W., Hashimoto-Tane A., Azuma M., Saito T. Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. J Exp Med 2012, 209:1201-1217.
27. Sheppard K.A., Fitz L.J., Lee J.M., Benander C., George J.A., Wooters J., et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett 2004, 574:37-41.
28. Parry R.V., Chemnitz J.M., Frauwirth K.A., Lanfranco A.R., Braunstein I., Kobayashi S.V., et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005, 25:9543-9553.
29. Honda T., Egen J.G., Lammermann T., Kastenmuller W., Torabi-Parizi P., Germain R.N. Tuning of antigen sensitivity by T cell receptor-dependent negative feedback controls T cell effector function in inflamed tissues. Immunity 2014, 40:235-247.
30. Butte M.J., Keir M.E., Phamduy T.B., Sharpe A.H., Freeman G.J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007, 27:111-122.
31. Francisco L.M., Salinas V.H., Brown K.E., Vanguri V.K., Freeman G.J., Kuchroo V.K., et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J Exp Med 2009, 206:3015-3029.
32. Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., et al. PD-L1 negatively regulates CD4 + CD25 + Foxp3+ tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J Clin Invest 2009, 119:551-564.
33. Park H.J., Park J.S., Jeong Y.H., Son J., Ban Y.H., Lee B.H., et al. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells. J Immunol 2015, 194:5801-5811.
34. Good-Jacobson K.L., Szumilas C.G., Chen L., Sharpe A.H., Tomayko M.M., Shlomchik M.J. PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells. Nat Immunol 2010, 11:535-542.
35. Sage P.T., Francisco L.M., Carman C.V., Sharpe A.H. The receptor PD-1 controls follicular regulatory T cells in the lymph nodes and blood. Nat Immunol 2013, 14:152-161.
36. Ciszak L., Frydecka I., Wolowiec D., Szteblich A., Kosmaczewska A. CTLA-4 affects expression of key cell cycle regulators of G0/G1 phase in neoplastic lymphocytes from patients with chronic lymphocytic leukaemia. Clin Exp Med 2015 May 25, [Epub ahead of print].
37. Pistillo M.P., Tazzari P.L., Palmisano G.L., Pierri I., Bolognesi A., Ferlito F., et al. CTLA-4 is not restricted to the lymphoid cell lineage and can function as a target molecule for apoptosis induction of leukemic cells. Blood 2003, 101:202-209.
38. Perez-Garcia A., Brunet S., Berlanga J.J., Tormo M., Nomdedeu J., Guardia R., et al. CTLA-4 genotype and relapse incidence in patients with acute myeloid leukemia in first complete remission after induction chemotherapy. Leukemia 2009, 23:486-491.
39. Shimauchi T., Kabashima K., Tokura Y. Adult T-cell leukemia/lymphoma cells from blood and skin tumors express cytotoxic T lymphocyte-associated antigen-4 and Foxp3 but lack suppressor activity toward autologous CD8+ T cells. Cancer Sci 2008, 99:98-106.
40. Wong H.K., Wilson A.J., Gibson H.M., Hafner M.S., Hedgcock C.J., Berger C.L., et al. Increased expression of CTLA-4 in malignant T-cells from patients with mycosis fungoides-cutaneous T cell lymphoma. J Invest Dermatol 2006, 126:212-219.
41. Kosmaczewska A., Frydecka I., Bocko D., Ciszak L., Teodorowska R. Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon-gamma production. Br J Haematol 2002, 118:202-209.
42. Bryan L.J., Gordon L.I. Blocking tumor escape in hematologic malignancies: the anti-PD-1 strategy. Blood Rev 2015, 29:25-32.
43. Green M.R., Monti S., Rodig S.J., Juszczynski P., Currie T., O'Donnell E., et al. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 2010, 116:3268-3277.
44. Twa D.D., Chan F.C., Ben-Neriah S., Woolcock B.W., Mottok A., Tan K.L., et al. Genomic rearrangements involving programmed death ligands are recurrent in primary mediastinal large B-cell lymphoma. Blood 2014, 123:2062-2065.
45. Steidl C., Shah S.P., Woolcock B.W., Rui L., Kawahara M., Farinha P., et al. MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers. Nature 2011, 471:377-381.
46. Hao Y., Chapuy B., Monti S., Sun H.H., Rodig S.J., Shipp M.A. Selective JAK2 inhibition specifically decreases Hodgkin lymphoma and mediastinal large B-cell lymphoma growth in vitro and in vivo. Clin Cancer Res 2014, 20:2674-2683.
47. Marzec M., Zhang Q., Goradia A., Raghunath P.N., Liu X., Paessler M., et al. Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-L1, B7-H1). Proc Natl Acad Sci U S A 2008, 105:20852-20857.
48. Hossain D.M., Dos Santos C., Zhang Q., Kozlowska A., Liu H., Gao C., et al. Leukemia cell-targeted STAT3 silencing and TLR9 triggering generate systemic antitumor immunity. Blood 2014, 123:15-25.
49. Green M.R., Rodig S., Juszczynski P., Ouyang J., Sinha P., O'Donnell E., et al. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy. Clin Cancer Res 2012, 18:1611-1618.
50. Kozako T., Yoshimitsu M., Fujiwara H., Masamoto I., Horai S., White Y., et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009, 23:375-382.
51. Ni L., Ma C.J., Zhang Y., Nandakumar S., Zhang C.L., Wu X.Y., et al. PD-1 modulates regulatory T cells and suppresses T-cell responses in HCV-associated lymphoma. Immunol Cell Biol 2011, 89:535-539.
52. Chen B.J., Chapuy B., Ouyang J., Sun H.H., Roemer M.G., Xu M.L., et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies. Clin Cancer Res 2013, 19:3462-3473.
53. Kondo A., Yamashita T., Tamura H., Zhao W., Tsuji T., Shimizu M., et al. Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 2010, 116:1124-1131.
54. Kronig H., Kremmler L., Haller B., Englert C., Peschel C., Andreesen R., et al. Interferon-induced programmed death-ligand 1 (PD-L1/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 2014, 92:195-203.
55. Wang L., Liu J.Q., Talebian F., Liu Z., Yu L., Bai X.F. IL-10 enhances CTL-mediated tumor rejection by inhibiting highly suppressive CD4 T cells and promoting CTL persistence in a murine model of plasmacytoma. Oncoimmunology 2015, 4.
56. Myklebust J.H., Irish J.M., Brody J., Czerwinski D.K., Houot R., Kohrt H.E., et al. High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells. Blood 2013, 121:1367-1376.
57. Ansell S.M., Hurvitz S.A., Koenig P.A., LaPlant B.R., Kabat B.F., Fernando D., et al. Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res 2009, 15:6446-6453.
58. Bashey A., Medina B., Corringham S., Pasek M., Carrier E., Vrooman L., et al. CTLA4 blockade with Ipilimumab to treat relapse of malignancy after allogeneic hematopoietic cell transplantation. Blood 2009, 113:1581-1588.
59. Davids M.S., Kim H.T., Costello C.L., Avigan D., Chen Y.B., Armand P., et al. A multicenter phase I study of CTLA-4 blockade with ipilimumab for relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Blood 2014, 124. [Abst 3964].
60. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008, 14:3044-3051.
61. Westin J.R., Chu F., Zhang M., Fayad L.E., Kwak L.W., Fowler N., et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 2014, 15:69-77.
62. Lesokhin A.M., Ansell S.M., Armand P., Scott E.C., Halwani A., Gutierrez M., et al. Preliminary results of a phase I study of nivolumab (BMS-936558) in patients with relapsed or refractory lymphoid malignancies. Blood 2014, 124. [Abst 291].
63. Armand P., Nagler A., Weller E.A., Devine S.M., Avigan D.E., Chen Y.B., et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial. J Clin Oncol 2013, 31:4199-4206.
64. Ansell S.M., Lesokhin A.M., Borrello I., Halwani A., Scott E.C., Gutierrez M., et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015, 372:311-319.
65. Moskowitz C.H., Ribrag V., Michot J.M., Martinelli G., Zinzani P.L., Gutierrez M., et al. PD-1 blockade with the monoclonal antibody pembrolizumab (MK-3475) in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: preliminary results from a phase 1b study (KEYNOTE-013). Blood 2014, 124. [Abst 290].
66. Okazaki T., Chikuma S., Iwai Y., Fagarasan S., Honjo T. A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application. Nat Immunol 2013, 14:1212-1218.
67. Chen D.S., Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013, 39:1-10.
68. Curran M.A., Montalvo W., Yagita H., Allison J.P. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107:4275-4280.
69. Sakuishi K., Apetoh L., Sullivan J.M., Blazar B.R., Kuchroo V.K., Anderson A.C. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010, 207:2187-2194.
70. Woo S.R., Turnis M.E., Goldberg M.V., Bankoti J., Selby M., Nirschl C.J., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res 2012, 72:917-927.
71. Schumacher T.N., Schreiber R.D. Neoantigens in cancer immunotherapy. Science 2015, 348:69-74.
72. Gubin M.M., Zhang X., Schuster H., Caron E., Ward J.P., Noguchi T., et al. Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature 2014, 515:577-581.
73. Das R., Verma R., Sznol M., Boddupalli C.S., Gettinger S.N., Kluger H., et al. Combination therapy with anti-CTLA-4 and anti-PD-1 leads to distinct immunologic changes in vivo. J Immunol 2015, 194:950-959.
74. Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Cowey C.L., Lao C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015, 373:1270-1271.
75. Postow M.A., Chesney J., Pavlick A.C., Robert C., Grossmann K., McDermott D., et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015, 372:2006-2017.
76. Zamarin D., Postow M.A. Immune checkpoint modulation: rational design of combination strategies. Pharmacol Ther 2015, 150:23-32.
77. Melero I., Hirschhorn-Cymerman D., Morales-Kastresana A., Sanmamed M.F., Wolchok J.D. Agonist antibodies to TNFR molecules that costimulate T and NK cells. Clin Cancer Res 2013, 19:1044-1053.
78. Curran M.A., Kim M., Montalvo W., Al-Shamkhani A., Allison J.P. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011, 6.
79. Linch S.N., Redmond W.L. Combined OX40 ligation plus CTLA-4 blockade: more than the sum of its parts. Oncoimmunology 2014, 3.
80. Buchan S.L., Manzo T., Flutter B., Rogel A., Edwards N., Zhang L., et al. OX40- and CD27-mediated costimulation synergizes with anti-PD-L1 blockade by forcing exhausted CD8+ T cells to exit quiescence. J Immunol 2015, 194:125-133.
81. Dubovsky J.A., Beckwith K.A., Natarajan G., Woyach J.A., Jaglowski S., Zhong Y., et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013, 122:2539-2549.
82. Sagiv-Barfi I., Kohrt H.E., Czerwinski D.K., Ng P.P., Chang B.Y., Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci U S A 2015, 112:E966-E972.
83. Coles S.J., Gilmour M.N., Reid R., Knapper S., Burnett A.K., Man S., et al. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 2015, 29:1952-1954.
84. Holmgaard R.B., Zamarin D., Munn D.H., Wolchok J.D., Allison J.P. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. J Exp Med 2013, 210:1389-1402.
85. Belladonna M.L., Grohmann U., Guidetti P., Volpi C., Bianchi R., Fioretti M.C., et al. Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol 2006, 177:130-137.
86. Spranger S., Koblish H.K., Horton B., Scherle P.A., Newton R., Gajewski T.F. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. J Immunother Cancer 2014, 2:3.
87. Sutmuller R.P., van Duivenvoorde L.M., van Elsas A., Schumacher T.N., Wildenberg M.E., Allison J.P., et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001, 194:823-832.
88. Klyushnenkova E.N., Riabov V.B., Kouiavskaia D.V., Wietsma A., Zhan M., Alexander R.B. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer. Prostate 2014, 74:1423-1432.
89. Rosalia R.A., Stepanek I., Pollakova V., Simova J., Bieblova J., Indrova M., et al. Administration of anti-CD25 mAb leads to impaired alpha-galactosylceramide-mediated induction of IFN-gamma production in a murine model. Immunobiology 2013, 218:851-859.
90. Noman M.Z., Desantis G., Janji B., Hasmim M., Karray S., Dessen P., et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 2014, 211:781-790.
91. De Veirman K., Van Valckenborgh E., Lahmar Q., Geeraerts X., De Bruyne E., Menu E., et al. Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol 2014, 4:349.
92. Gorgun G., Samur M.K., Cowens K.B., Paula S., Bianchi G., Anderson J.E., et al. Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res 2015, 21:4607-4618.
93. Lugade A.A., Moran J.P., Gerber S.A., Rose R.C., Frelinger J.G., Lord E.M. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
94. Dewan M.Z., Galloway A.E., Kawashima N., Dewyngaert J.K., Babb J.S., Formenti S.C., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
95. Postow M.A., Callahan M.K., Barker C.A., Yamada Y., Yuan J., Kitano S., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
96. Golden E.B., Demaria S., Schiff P.B., Chachoua A., Formenti S.C. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res 2013, 1:365-372.
97. Youngblood B., Oestreich K.J., Ha S.J., Duraiswamy J., Akondy R.S., West E.E., et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011, 35:400-412.
98. Yang H., Bueso-Ramos C., DiNardo C., Estecio M.R., Davanlou M., Geng Q.R., et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 2014, 28:1280-1288.
99. Rosenblatt J., Glotzbecker B., Mills H., Vasir B., Tzachanis D., Levine J.D., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J Immunother 2011, 34:409-418.
100. Zhang C., Wang W., Qin X., Xu Y., Huang T., Hao Q., et al. B7-H1 protein vaccine induces protective and therapeutic antitumor responses in SP2/0 myeloma-bearing mice. Oncol Rep 2013, 30:2442-2448.
101. Met O., Wang M., Pedersen A.E., Nissen M.H., Buus S., Claesson M.H. The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling. Cancer Lett 2006, 231:247-256.
102. Voo K.S., Foglietta M., Percivalle E., Chu F., Nattamai D., Harline M., et al. Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma. Int J Cancer 2014, 135:2834-2846.
103. Fu J., Kanne D.B., Leong M., Glickman L.H., McWhirter S.M., Lemmens E., et al. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade. Sci Transl Med 2015, 7. [283ra52].
104. Norde W.J., Maas F., Hobo W., Korman A., Quigley M., Kester M.G., et al. PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res 2011, 71:5111-5122.
105. John L.B., Devaud C., Duong C.P., Yong C.S., Beavis P.A., Haynes N.M., et al. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells. Clin Cancer Res 2013, 19:5636-5646.
106. Burga R.A., Thorn M., Point G.R., Guha P., Nguyen C.T., Licata L.A., et al. Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T. Cancer Immunol Immunother 2015, 64:817-829.
107. Saenger Y.M., Wolchok J.D. The heterogeneity of the kinetics of response to Ipilimumab in metastatic melanoma: patient cases. Cancer Immun 2008, 8:1.
108. Postow M.A., Callahan M.K., Wolchok J.D. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015, 33:1974-1982.